Evolent Health Inc. (NYSE:EVH) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $24.72 and last traded at $24.47, with a volume of 98,520 shares. The stock had previously closed at $24.00.

EVH has been the topic of a number of research reports. Zacks Investment Research lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. Canaccord Genuity reiterated a “buy” rating on shares of Evolent Health in a report on Friday, May 13th. FBR & Co reiterated a “buy” rating on shares of Evolent Health in a report on Saturday, May 14th. Leerink Swann reiterated a “buy” rating and set a $20.00 target price on shares of Evolent Health in a report on Monday, May 16th. Finally, Jefferies Group initiated coverage on shares of Evolent Health in a report on Tuesday. They set a “buy” rating and a $28.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $22.17.

The stock has a market cap of $1.44 billion and a price-to-earnings ratio of 6.39. The firm’s 50 day moving average price is $19.45 and its 200 day moving average price is $13.32.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. The firm earned $49.50 million during the quarter, compared to analyst estimates of $47.40 million. Evolent Health’s revenue was up 33.8% compared to the same quarter last year. Equities research analysts anticipate that Evolent Health Inc. will post ($0.62) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Evolent Health stock. Schroder Investment Management Group boosted its position in shares of Evolent Health Inc. (NYSE:EVH) by 120.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 355,922 shares of the company’s stock after buying an additional 194,222 shares during the period. Schroder Investment Management Group owned about 0.60% of Evolent Health worth $4,310,000 at the end of the most recent reporting period.

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.